Comparison
Semax vs. Terlipressin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
80714-61-0
14636-12-5
Molecular weight
813.92 g/mol
1227.37 g/mol
Half-life
0.3 h
no data
Sequence
Met-Glu-His-Phe-Pro-Gly-Prono data
Mechanism of action
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Terlipressin
Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
1
of which in humans
2
1
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Semax and Terlipressin?
- Semax is classified as "Research other", while Terlipressin is classified as "Research other". Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Semax or Terlipressin?
- The highest available evidence level is "Human trial" for Semax and "Human RCT" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Semax and Terlipressin in Germany and the United States?
- Germany: Semax — Unapproved, Terlipressin — Prescription. United States: Semax — Unapproved, Terlipressin — Prescription. These are factual summaries with source and review date on the individual pages.